Achieved Full Year 2022 Record Revenue and Adjusted EBITDA for Full Year 2022 Expect 2023 Revenue of $190-200 million and Adjusted EBITDA of $56-60 million Significantly Increased Trading Liquidity with Recent Successful Secondary Offering IRVING, Texas --(BUSINESS WIRE)--Mar.

Study reports the patient also experienced “increased energy, recovery, and benefits to his sleep apnea” as well as being able to “remove supportive fracture hardware in one year” IRVING, Texas --(BUSINESS WIRE)--Mar. 27, 2023-- In a case study, a 54-year-old male patient with a spontaneous

IRVING, Texas --(BUSINESS WIRE)--Mar. 2, 2023-- biote   Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading innovator in preventive health care through the delivery of personalized hormone therapy, today announced its participation in the 35 th Annual Roth Conference , to be held March

IRVING, Texas --(BUSINESS WIRE)--Feb. 9, 2023-- Biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the Company will provide fourth quarter and full year financial results on

IRVING, Texas --(BUSINESS WIRE)--Jan. 9, 2023-- biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the closing of its previously announced underwritten public offering of 8,500,000

IRVING, Texas --(BUSINESS WIRE)--Jan. 5, 2023-- biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the pricing of an underwritten public offering of its Class A common stock by

IRVING, Texas --(BUSINESS WIRE)--Nov. 10, 2022-- biote   Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading innovator in preventive health care through the delivery of personalized hormone therapy, today announced its participation in the Jefferies London Healthcare Conference , November

Strong Third Quarter Revenue of $42 million Driven by Growth in Procedures 2022 Revenue and Adjusted EBITDA Expected at Upper End of Guidance IRVING, Texas --(BUSINESS WIRE)--Nov. 8, 2022-- Biote (NASDAQ: BTMD), a leading provider of preventive health care through the delivery of personalized

IRVING, Texas --(BUSINESS WIRE)--Nov. 7, 2022-- biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading innovator in preventive health care through the delivery of personalized hormone therapy, today announced the appointment of Debby Morris to Biote’s Board of Directors. Ms.

IRVING, Texas --(BUSINESS WIRE)--Oct. 31, 2022-- biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the Company will provide third quarter financial results on Tuesday, November 8,